Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

Journal of thrombosis and thrombolysis - 1 Feb 2007

Eroglu Aydan, Ulu Arzu, Cam Ragip, Kurtman Cengiz, Akar Nejat

Abstract excerpt

AIMS: Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control. MATERIALS AND METHODS: We have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor V

Share to Neoplasms

Share to Odds Ratio

Share to Prothrombin

Share to Thromboembolism

Share to Venous Thrombosis

Source

Identifiers

PMID: 17106650
DOI: 10.1007/s11239-006-9001-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.PMID 17106650Read ↗

Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients.Semantic proximity Read ↗

Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients?Semantic proximity Read ↗

Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis.Semantic proximity Read ↗

Malignancies, prothrombotic mutations, and the risk of venous thrombosis.Semantic proximity Read ↗

Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).Semantic proximity Read ↗

Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study.Semantic proximity Read ↗

Prothrombotic genotypes and risk of venous thromboembolism in cancer.Semantic proximity Read ↗

Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma.Semantic proximity Read ↗

No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients.Semantic proximity Read ↗

Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

The efficacy of tissue factor -603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.Semantic proximity Read ↗

Thrombophilia and cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.